Limba
|
VV116, a promising orally administered anti-SARS-CoV-2 nucleosidedrug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerasethrough its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
Price | 2.356,00 RON (preturile sunt fara TVA) |
---|---|
Description |
VV116, a promising orally administered anti-SARS-CoV-2 nucleosidedrug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerasethrough its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM. |